Form 4: Hims & Hers Health CEO Andrew Dudum Executes Stock Option and Sells Shares Under 10b5-1 Plan

Hims & Hers Health CEO Andrew Dudum exercised stock options and sold shares of Class A Common Stock on November 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On November 5, 2024, Andrew Dudum, CEO of Hims & Hers Health, Inc., executed stock options to acquire 188,888 shares of Class A Common Stock at an exercise price of $2.43 per share.
• Dudum also sold shares of Class A Common Stock at varying prices ranging from $19.54 to $22.13 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted by Dudum on November 29, 2023.
• Following these transactions, Dudum directly owns 67,015 shares of Class A Common Stock and indirectly owns millions of shares through various trusts.
• The reported transactions include sales of 81,114 shares at $20.0665, 50,928 shares at $21.1869, 12,402 shares at $21.763, 63,798 shares at $20.0502, 99,987 shares at $21.1946, and 25,103 shares at $21.7596.
• Dudum continues to hold significant indirect ownership through multiple trusts, including the Andrew Dudum 2015 Trust, AD 2022 GRATs, AD 2021 GRATs, Dudum Family Community Property Trust, AD 2023 GRAT, Richard M. Dudum Irrevocable Trust, and Dudum Family Heritage Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, but the sale of shares by the CEO could raise some concerns among investors.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
• Dudum continues to hold a significant number of shares, indicating continued alignment with the company's success.

Negatives

• The sale of shares by the CEO could be perceived negatively by some investors, potentially signaling a lack of confidence, although the 10b5-1 plan mitigates this concern.

Risks

• Continued sales of shares by insiders, even under a 10b5-1 plan, could create downward pressure on the stock price.
• Investor sentiment could be negatively impacted if the market interprets the sales as a lack of confidence in the company's future prospects.

Industry Context

Insider transactions are common and closely monitored in the healthcare and telehealth industry. Rule 10b5-1 plans are frequently used by executives to manage their stock holdings while avoiding accusations of insider trading.

Comparison to Industry Standards

• Comparing insider trading activity to similar companies like Teladoc Health (TDOC) or GoodRx (GDRX) can provide context.
• Monitoring the volume and frequency of insider sales relative to overall trading volume is important.
• The use of a 10b5-1 plan is a standard practice among public company executives.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sales, although the existence of a 10b5-1 plan should mitigate concerns.
• Employees may be indirectly affected by any changes in stock price resulting from these transactions.

Key Dates